Literature DB >> 7860158

Immunization of 6 and 9 month old infants with AIK-C, Edmonston-Zagreb, Leningrad-16 and Schwarz strains of measles vaccine.

V M Bolotovski1, M Grabowsky, C J Clements, P Albrecht, E R Brenner, A I Zargaryantzs, S K Litvinov, I V Mikheyeva.   

Abstract

BACKGROUND: Measles kills more than 1 million infants per year and is particularly lethal in infants < 1 year old in developing countries. Recent reports have suggested that measles vaccines of different strains and titre differ in their immunogenicity in young infants. We sought to identify strains and titres of measles vaccines which would be effective in 6 and 9 month old infants.
METHODS: We conducted a randomized trial of AIK-C, Edmonston-Zagreb (EZ), Leningrad-16 and Schwarz strains of measles vaccine at different titres in 1202 6 month old and 1250 9 month old infants. Antibody levels were measured by haemagglutination inhibition assay. Seroconversion was defined as a change from seronegative to seropositive or a fourfold rise in titre above the expected level after antibody decay (assumed antibody half-life = 6 weeks). Chi-square tests were used to compare seroconversion rates and rates of adverse reactions among the groups. Comparison of geometric mean titres (GMT) was done by the Student's t-test.
RESULTS: No severe or unusual adverse reactions occurred during the 6 weeks after vaccination. All strains induced high seroconversion rates in 9 month old infants. In 6 month olds, medium- and standard-titre AIK-C induced the highest rates of seroconversion. Antibody titres at 6 weeks after vaccination were highest in recipients of Schwartz vaccine and lowest for EZ vaccine recipients.
CONCLUSIONS: Standard-titre AIK-C may be more effective than other measles vaccine strains for early measles immunization and should be evaluated further for efficacy, long-term immunogenicity, and long-term safety.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7860158     DOI: 10.1093/ije/23.5.1069

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  11 in total

1.  The WHO Global Programme for Vaccines and Immunization Vaccine Trial Registry.

Authors:  S E Robertson; M V Mayans; S Horsfall; P F Wright; J Clemens; B Ivanoff; P H Lambert
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

Review 2.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

3.  Comparison of AIK-C measles vaccine in infants at 6 months with Schwarz vaccine at 9 months: a randomized controlled trial in Ghana.

Authors:  F K Nkrumah; M Osei-Kwasi; S K Dunyo; K A Koram; E A Afari
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

4.  Tolerability of Early Measles-Mumps-Rubella Vaccination in Infants Aged 6-14 Months During a Measles Outbreak in The Netherlands in 2013-2014.

Authors:  Nicoline A T van der Maas; T Woudenberg; S J M Hahné; H E de Melker
Journal:  J Infect Dis       Date:  2015-12-21       Impact factor: 5.226

5.  Simultaneous Administration of Recombinant Measles Viruses Expressing Respiratory Syncytial Virus Fusion (F) and Nucleo (N) Proteins Induced Humoral and Cellular Immune Responses in Cotton Rats.

Authors:  Yoshiaki Yamaji; Akihito Sawada; Yosuke Yasui; Takashi Ito; Tetsuo Nakayama
Journal:  Vaccines (Basel)       Date:  2019-03-04

6.  AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats.

Authors:  Akihito Sawada; Katsuhiro Komase; Tetsuo Nakayama
Journal:  Vaccine       Date:  2010-12-24       Impact factor: 3.641

7.  Recombinant Measles AIK-C Vaccine Strain Expressing the prM-E Antigen of Japanese Encephalitis Virus.

Authors:  Akira Higuchi; Hiroko Toriniwa; Tomoyoshi Komiya; Tetsuo Nakayama
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

8.  Is early measles vaccination associated with stronger survival benefits than later measles vaccination?

Authors:  Jesper Sloth Hansen; Sanne Marie Thysen; Amabelia Rodrigues; Cesario Martins; Ane Bærent Fisker
Journal:  BMC Public Health       Date:  2018-08-07       Impact factor: 3.295

9.  Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis.

Authors:  Sara Carazo; Marie-Noëlle Billard; Amélie Boutin; Gaston De Serres
Journal:  BMC Infect Dis       Date:  2020-03-29       Impact factor: 3.090

10.  Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis.

Authors:  Laura M Nic Lochlainn; Brechje de Gier; Nicoline van der Maas; Peter M Strebel; Tracey Goodman; Rob S van Binnendijk; Hester E de Melker; Susan J M Hahné
Journal:  Lancet Infect Dis       Date:  2019-09-20       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.